Results 121 to 130 of about 2,303 (187)

Detection of nirsevimab-resistant RSV-B variants in children carrying the F:N201T substitution through genomic surveillance, Spain, 2025/26 season. [PDF]

Euro Surveill
Iglesias-Caballero M, Infantes JA, Campoy A, Camarero-Serrano S, Moreno S, Cano O, Vallejo-Palma G, González-Velasco C, Gaona C, Camacho-Martinez P, Merino-Diaz L, Vázquez-Morón S, Pozo F, Lepe JA, Mas V, Casas I.   +15 more
europepmc   +1 more source

Impact du nirsevimab sur les hospitalisations pour bronchiolites à VRS au CHU de Clermont-Ferrand durant l'hiver 2023-2024

Contexte : le virus respiratoire syncytial (VRS) est la cause la plus fréquente de bronchiolite chez les nourrissons pouvant causer des atteintes graves allant jusqu’au décès.
Couteau, Lorène
core   +1 more source

Acute viral bronchiolitis before and after implementation of <i>nirsevimab</i> prophylaxis in Italy: a multicentre retrospective cohort study. [PDF]

Lancet Reg Health Eur
Spatuzzo M, Corsello A, Riccò M, Bonci E, Di Francesco D, Strati MF, Amodio G, Manzalini R, Costantini E, Mazzotti S, Renni M, Coralluzzo F, Langone L, Fiumicelli E, Albonico G, Adornato S, Passarella V, Piras A, Forcucci F, Capuano MC, Basile A, Albini M, Cafforio A, Coppola C, Palmoni M, Bertolucci G, Bertolo S, Di Febo C, Donato A, Di Pasquale G, Toscano F, Tolfa G, Arpinelli M, Marseglia GL, Agostiniani R, Midulla F, ONSP-RSV Study Group.   +36 more
europepmc   +1 more source

Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey. [PDF]

PLoS One
Di Chiara C, Piché-Renaud PP, Rigamonti V, Cantarutti A, Calvo C, Rivero Calle I, Soriano-Arandes A, Giaquinto C, Cantarutti L, Donà D, Lo Vecchio A, Hadjipanayis A, Pana ZD, Kopsidas I, Rose A, Tagarro A, Morris SK.   +16 more
europepmc   +1 more source

Nirsevimab rollout in the Gulf Cooperation Council, scoping review protocol

Protocol for a PRISMA-ScR scoping review of nirsevimab implementation across the six Gulf Cooperation Council countries during the 2024 to 2025 and 2025 to 2026 RSV seasons, with cost-effectiveness modeling for Kuwait, Qatar, Bahrain, and Oman ...
Rabia Shah
core  

Evaluation of Nirsevimab and hRSV Severity Risk Factors on hRSV Admissions

Human Respiratory Syncytial Virus (hRSV) is a common respiratory pathogen, primarily affecting infants and young children. In the United States, hRSV is a leading cause of hospitalization in this age group. Currently, there is no treatment for acute hRSV.
Ogrin, Sara, Leffler, Luke, Grofvert, John   +2 more
core  

Guideline for Weighing of Infants for Nirsevimab Administration.

Purpose To provide a standardised approach to determine the correct Nirsevimab dose for infants attending a catch-up clinic including mobile vaccination clinics: ensuring accurate dosing while avoiding unnecessary ...
Health Protection Surveillance Centre (HPSC)
core  

Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network. [PDF]

Lancet Reg Health West Pac
Wadia U, Richmond PC, Britton PN, Carr J, Clark JE, Crawford NW, Hung TY, Marshall HS, Macartney KK, Wood NJ, McMullan BJ, Moore HC, Effler PV, Cheng AC, Blyth CC, PAEDS-FluCAN Network.   +15 more
europepmc   +1 more source

Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia. [PDF]

Infect Dis Ther
Carrasquilla-Sotomayor M, Alvis-Zakzuk NJ, Coronell-Rodríguez W, Arias A, Moyano-Tamara L, Alvarado-Gonzalez JC, De la Hoz-Restrepo F, Alvis-Guzman N.   +7 more
europepmc   +1 more source

Impact of Universal Nirsevimab Immunoprophylaxis on RSV-Related Hospitalizations in Infants: A Two-Season Multicenter Study in Northern Italy. [PDF]

Pathogens
Gianotto NR, Ragusa N, Deut V, Mattivi C, Cherubini Scarafoni M, Dominici S, Mazzetti G, Sandei M, Lo Presti C, Manuela C, Calvo MM, Berger M.   +11 more
europepmc   +1 more source